Clinical Trials Directory

Trials / Completed

CompletedNCT05031832

Chemsex Engagement and HIV Biomedical Prevention in MSM

The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM

Status
Completed
Phase
Study type
Observational
Enrollment
733 (actual)
Sponsor
Chinese University of Hong Kong · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Accepted

Summary

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTHIV testHIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status

Timeline

Start date
2021-06-01
Primary completion
2024-10-02
Completion
2024-12-31
First posted
2021-09-02
Last updated
2025-01-23

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT05031832. Inclusion in this directory is not an endorsement.